Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

Movement Disorders

Volumn 20, Issue 1, 2005, Pages 104-105

  Fernandez, Hubert H ^a   Trieschmann, Martha E ^b   Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Atypical antipsychotic; Clozapine; Discontinuation; Parkinson; Psychosis; Quetiapine

Indexed keywords

CLOZAPINE; LEVODOPA; QUETIAPINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; REBOUND; RELAPSE;

EID: 14044279922     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20260     Document Type: Article

References (14)

1. Sanchez-Ramos J, Ortoll R, Paulson G. Visual hallucinations associated with Parkinson's disease. Arch Neurol Psychiatry 1996; 53:1265-1268.
2. Klawans H. Levodopa-induced psychosis. Psychiatry American 1978;8:447-471.
3. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
4. Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson's disease. Expert Opin Pharmacother 2003;4: 1747-1761.
5. Fernandez HH, Trieschmann ME, Friedman JH. The treatment of psychosis in Parkinson's disease: safety considerations. Drug Safety 2003;26:643-659.
6. Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999;11:467-483.
7. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
8. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patient with advanced Parkinson's disease. Neurology 1995; 45:669-671.
9. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-2082.
10. Alvir JMA, Lieberman JA, Safferman AZ. Clozapine induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167.
11. Fernandez HH, Friedman JH, Lannon MC, Abbott BP. Clozapine replacement by quetiapine for drug-induced psychosis in Parkinson's disease. Mov Disord 2000;3:579-581.
12. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487.
13. Fernandez HH. Quetiapine for L-dopa induced psychosis in PD. Neurology 2000;55:899.
14. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60: 1756-1761.